For its third fiscal quarter (ending September 30), United Therapeutics Corp (NASDAQ: UTHR) has reported a 21% increase in E.P.S. from $5.71 a year ago to $6.93 in the current quarter. E.P.S. were $24.35 for the latest four quarters through September 30 versus $19.32 for the same period a year ago — an increase of 26%.
Recent Price Action
On 10/30/24, United Therapeutics Corp (NASDAQ: UTHR) stock enjoyed a large increase of 2.4%, closing at $361.40. Moreover, this advance was accompanied by unusually high trading volume at 158% of normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -2.4% during the last week.
Current PriceTarget Research Rating
UTHR’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be an important Value Builder.
United Therapeutics has a current Value Trend Rating of A (Highest Rating). This rating combines complementary signals from two proprietary PTR measures of a stock’s attractiveness. United Therapeutics has a slightly positive Appreciation Score of 69 and a very high Power Rating of 88, producing the Highest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of A. This review will be completed in the next several days.
Be the first to comment